33 results on '"Maughan T"'
Search Results
2. Next generation radiotheranostics promoting precision medicine
3. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
4. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
5. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
6. Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
7. 7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis
8. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
9. 515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
10. Research-intensive cancer care in the NHS in the UK
11. O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)
12. Pancreatic Cancer within a UK Cancer Network with Special Emphasis on Locally Advanced Non-metastatic Pancreatic Cancer
13. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
14. LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
15. 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials
16. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
17. 431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC)
18. 430P Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer
19. 382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring
20. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database
21. PD-002 - CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial
22. Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET)
23. 483PD - Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial
24. 493P - Surgical quality and the impact of liver resection on outcome in the new EPOC study
25. 509P - FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS
26. 480P - MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
27. 2104 Derived neutrophil to lymphocyte ratio is not predictive for use of a continuous or intermittent first-line oxaliplatin/fluoropyrimidine combination in patients with advanced colorectal cancer: A post-hoc analysis of the MRC COIN study
28. P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer – functional imaging is prognostic and provides proof of mechanism
29. X-ACT: An important step on an unfinished journey
30. 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
31. 277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial
32. The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy
33. OP13. Economics of the MRC colorectal working party CR06 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.